VassiliosA.DimitropoulosMD
Dermatology • Michigan City, INDermatologic Surgery
Assistant Professor and Director of Mohs and Dermatological Surgery University of Illinois Chicago
Dr. Dimitropoulos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10282 W 400 N
Michigan City, IN 46360Phone+1 773-351-2862Fax+1 773-358-2767
Summary
- Dr. Vassilios Dimitropoulos is a dermatologist in Saint Joseph, MI and is affiliated with multiple hospitals in the area, including Lakeland Medical Center, St. Joseph, AMITA Health Adventist Medical Center Bolingbrook, Evanston Hospital, AMITA Health Resurrection Medical Center - Chicago, NorthShore Skokie Hospital, Highland Park Hospital, Glenbrook Hospital, and Battle Creek Veterans Affairs Medical Center. He received his medical degree from Rush Medical College and has been in practice 16 years. He specializes in dermatologic surgery and is experienced in sclerotherapy, general dermatology, dermatologic surgery, cosmetic dermatology, and cryosurgery.
Education & Training
University of MichiganResidency, Dermatology, 2002 - 2005
Rush University Medical CenterInternship, Internal Medicine, 2001 - 2002
Rush Medical College of Rush University Medical CenterClass of 2001
Certifications & Licensure
IL State Medical License 2005 - 2026
MI State Medical License 2004 - 2026
IN State Medical License 2020 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) Start of enrollment: 2019 Sep 24
- Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2020 Feb 11
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsReasons behind the ink.Dimitropoulos, Brown Cw, Ressa Na, Newman M
Cutis. 2016-11-01 - 4 citationsExcisional Debulking and Electrosurgery of Otophyma and Rhinophyma.Steven L. Kahn, Joshua O. Podjasek, Vassilios A. Dimitropoulos, Clarence W. Brown
Dermatologic Surgery. 2016-01-01 - 13 citationsNatural rubber latex allergy.Steven L. Kahn, Joshua O. Podjasek, Vassilios A. Dimitropoulos, Clarence W. Brown
Disease-a-Month. 2016-01-01
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
